Snowball logo
logo
YAG2_logo

Atossa Therapeutics Inc

€6.75€0.00  (0%)
Estimate
EPS
-2.91
Beta
1.336
About the company
Ticker
YAG2
ISIN
US04962H5063
Country
United States of America
Sector (GICS)
Healthcare
Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.

Frequently asked questions

What sector does Atossa Therapeutics Inc (YAG2) operate in?

Atossa Therapeutics Inc belongs to the Healthcare sector and operates in the Biotechnology industry.

What is Atossa Therapeutics Inc (YAG2) current stock price?

As of the latest data, Atossa Therapeutics Inc stock price is €6.75, with a previous close of €6.75.

What is Atossa Therapeutics Inc (YAG2) current market capitalization?

Atossa Therapeutics Inc market cap is approximately 58.13 million.

What is Atossa Therapeutics Inc (YAG2) Earnings Per Share (EPS)?

The trailing EPS is -€2.91.

Does Atossa Therapeutics Inc (YAG2) pay dividends?

No. Atossa Therapeutics Inc does not pay a dividend.

What is Atossa Therapeutics Inc (YAG2) beta (volatility) score?

Atossa Therapeutics Inc has a beta of 1.336, suggesting it is more volatile than the market.